Hong Kong Stock Movement: WuXi AppTec's performance exceeded expectations, with a stock price increase of 13.57%! Investment banks are raising ratings, and market enthusiasm is high

Hong Kong Stock Movement WuXi AppTec rose 13.57%. Based on recent key news: On April 27, WuXi AppTec announced its Q1 2026 results, with operating revenue of 12.436 billion yuan, a year-on-year increase of 28.81%; net profit of 4.652 billion yuan, a year-on-year increase of 26.68%. The growth in performance is mainly attributed to the strengthening of the CRDMO business model and improvements in production efficiency. Source: Zhitong Finance On April 28, WuXi AppTec's stock price surged significantly, opening up 8.02%, and recorded multiple large transactions during the day, indicating a positive market reaction to its performance. Source: Economic Information Daily On April 28, several investment banks, including Morgan Stanley and Goldman Sachs, raised their ratings and target prices for WuXi AppTec, believing its performance exceeded expectations and that its stock price is likely to continue rising in the future. Source: Morgan Stanley, Goldman Sachs Stocks with High Trading Volume in the Industry WuXi Biologics rose 1.56%. Based on recent key news: On April 28, WuXi AppTec released a strong financial report, with Q1 revenue of 12.436 billion yuan, a year-on-year increase of 28.81%, and net profit of 4.652 billion yuan, a year-on-year increase of 26.68%. This performance exceeded market expectations, driving up WuXi Biologics' stock price. Source: Zhitong Finance On April 28, the Hong Kong stock market adjusted, but the WuXi sector rose against the trend, with WuXi AppTec up 15% and WuXi Biologics rising over 2%. The performance of WuXi AppTec provided positive market sentiment for WuXi Biologics. Source: Investing.com On April 27, WuXi AppTec announced its Q1 2026 report, showing a significant improvement in profitability, with a profit margin exceeding 37% and ample order reserves, providing high certainty for future growth. This news boosted market confidence in WuXi Biologics. Source: Times Online WuXi AppTec rose 2.33%. Based on recent key news: On April 28, WuXi AppTec announced its Q1 financial report, with operating revenue increasing by 28.81% year-on-year and net profit increasing by 26.68%, driving up WuXi sector stocks. WuXi AppTec's stock price rose over 4%, reflecting the market's positive response to its financial performance. Source: Investing.com On April 28, Goldman Sachs released a report maintaining a buy rating for WuXi AppTec, with a target price of HKD 85.9. This rating supported investor confidence in the stock, further driving up its price. Source: Goldman Sachs Research Report On April 27, the overall Hong Kong stock market adjusted, but the WuXi sector rose against the trend, with WuXi AppTec's stock price increasing, demonstrating its resilience in market fluctuations. Source: Investing.com Kanglong Huacheng rose 5.73%. Based on recent key news: On April 28, Kanglong Chemical's stock price rose against the market trend, increasing by 6.4% in half a day, returning above multiple moving averages, indicating enhanced market confidence in its future performance. Source: Economic Information Daily On April 27, Goldman Sachs released a research report, rating Kanglong Chemical as a buy with a target price of HKD 31, further boosting market optimism for the stock. Source: Goldman Sachs On April 28, while the overall Hong Kong stock market faced pressure, Kanglong Chemical stood out, becoming one of the most actively traded call warrants in the market, reflecting investors' positive outlook on its future trend. Source: Economic Information Daily. The investment rating for the healthcare sector has been upgraded, enhancing market confidence. Stocks Ranked Among the Top by Market Capitalization in the Industry Tigermed rose by 3.54%. Based on recent key news: On April 27, Goldman Sachs released a research report, rating Tigermed as a buy with a target price of HKD 61.4. This rating has boosted market confidence in the stock, driving its price up. Recently, the overall performance of the mainland healthcare sector has been strong, with investors holding an optimistic view on the industry's prospects, further supporting Tigermed's stock price increase. Market expectations for Tigermed's future growth potential have strengthened, especially with progress in innovative drug development, attracting more capital inflow. The healthcare sector has performed strongly, with significant capital inflow